2018
Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals
Justice AC, Gordon KS, Skanderson M, Edelman EJ, Akgün KM, Gibert CL, Re V, Rimland D, Womack JA, Wyatt CM, Tate JP, Team V. Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals. AIDS 2018, 32: 739-749. PMID: 29543653, PMCID: PMC5868488, DOI: 10.1097/qad.0000000000001756.Peer-Reviewed Original ResearchConceptsAdverse health outcomesHIV statusUninfected individualsVACS IndexMedication countUS Veterans Affairs Healthcare SystemHealth outcomesVeterans Affairs Healthcare SystemRisk of hospitalizationSeverity of illnessHIV-1 RNAHIV-positive individualsRisk of mortalityDose responseRace/ethnicityPolypharmacyFiscal year 2009HospitalizationMedicationsMortalityHealthcare systemAntiretroviralsOutcomesAssociationRisk
2015
Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients
Weisberg DF, Gordon KS, Barry DT, Becker WC, Crystal S, Edelman EJ, Gaither J, Gordon AJ, Goulet J, Kerns RD, Moore BA, Tate J, Justice AC, Fiellin DA. Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2015, 69: 223-233. PMID: 26009831, PMCID: PMC4446730, DOI: 10.1097/qai.0000000000000591.Peer-Reviewed Original ResearchConceptsLong-term opioidsMorphine equivalent daily doseOpioid receiptRisk of deathLong-term prescriptionUninfected patientsOpioid dosesAntiretroviral therapyHazard ratioDaily dosePropensity scoreHigher opioid dosesCause mortalityHIV statusAvailable patientsMortality riskOpioidsHIVPatientsProspective analysisMortalityBenzodiazepinesDosesDeathRisk